Pancreatic Cancer Survival in Elderly Patients Treated With Chemotherapy
Pancreatic Cancer Survival in Elderly Patients Treated With Chemotherapy
复制标题
DOI：
10.1097/mpa.0000000000000091
复制
发表时间：
2014-03-01
期刊：
影响因子：
2.9
通讯作者：
Gress, Todd
中科院分区：
文献类型：
--
作者：
Sehgal, Rajesh;Alsharedi, Mohamed;Gress, Todd
目的胰腺癌是多发于老年人的致死性疾病。与日常实践相比，临床治疗试验中老年患者的数量少得不成比例。这项回顾性研究评估了不同年龄组化疗交付率和相关生存率的差异。方法收集1993 ~ 2008年胰腺癌患者的癌症信息资源档案资料。患者分为3个年龄组，分别为50岁以下的A组，50 ~ 70岁的B组，70岁以上的C组。结果16694例患者资料完整。C组为44%，C组为38%，A组为69%。多因素分析显示，所有组的化疗获益相似，如下：C组（风险比[HR]为0.51）、A组（风险比为0.74）和B组（风险比为0.55）。结论与年轻患者相比，老年胰腺癌患者接受治疗的频率较低。然而，接受化疗的老年患者也获得了类似的益处。需要随机临床试验来评估老年患者的胰腺癌治疗，特别是考虑到胰腺癌在晚年的发病率越来越高。
ObjectivesPancreatic cancer is a lethal disease mostly affecting elderly people. Clinical trials on treatment contain disproportionately fewer elderly patients compared with everyday practice. This retrospective study evaluates differences in the rates of chemotherapy delivered and associated survival in different age groups.MethodsData were collected from the Cancer Information Resource Files on patients diagnosed with pancreatic cancer from 1993 to 2008. Patients were divided into 3 age groups, namely, A with younger than 50 years, B with 50 to 70 years old, and C with older than 70 years.ResultsComplete data were available on 16,694 patients. Forty-four percent were in group C.Chemotherapy was given to 38% of patients in group C versus 69% of patients in group A. A multivariate analysis revealed a similar chemotherapy benefit in all groups, as follows: group C (hazard ratio [HR], 0.51), group A (HR, 0.74), and group B (HR, 0.55).ConclusionsWe found that elderly patients with pancreatic cancer receive treatment less frequently compared with younger patients. However, elderly patients receiving chemotherapy derive similar benefits. Randomized clinical trials are needed to evaluate pancreatic cancer treatment in the elderly patients, particularly given the increasing occurrence of pancreatic cancer in later life.